Together, these considerations provide a rationale for incorporating SNHG5–GNB2 status into future biomarker-driven trials that test combinations of lncRNA-targeted therapeutics, pathway inhibitors and immunotherapy in metastatic CRC. The gene discussed is GNB2; the disease is colorectal carcinoma.